Sinonasal Cancers: Single Center Experience


Camoz E. S., ATEŞ Ö., KILIÇ C., GÖKSEL F., ATASEVER AKKAŞ E., Onur I. D., ...Daha Fazla

Indian Journal of Otolaryngology and Head and Neck Surgery, cilt.77, sa.8, ss.2759-2765, 2025 (ESCI, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 77 Sayı: 8
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1007/s12070-025-05531-3
  • Dergi Adı: Indian Journal of Otolaryngology and Head and Neck Surgery
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Sayfa Sayıları: ss.2759-2765
  • Anahtar Kelimeler: Maxillary sinus carcinoma, Diplopia, Induction chemotherapy, Nasal carcinoma
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

To share our experience of sinonasal cancer management as a tertiary center.This is a retrospective study from a single tertiary center. The staging was performed according to the AJCC, 8th edition.A total of twenty-six patients were included in the study. The majority of the patients were male (76.9%), with the maxillary sinus as the primary tumor being predominant (80.8%), as was squamous cell histology (65.5%). T4 tumors at diagnosis accounted for 61.5% of the patients. The local recurrence rate was 23.1%. Induction chemotherapy was the initial treatment choice for 11.5% (n = 3) of the patients. Primary surgery was selected for 7.7% of the patients, and chemoradiotherapy was the treatment choice for 53.8%. The median follow-up duration was 56 months (95%CI: 29.8–82.1). The median overall survival (OS) was not reached, with 61.5% of patients remaining alive. The median disease-free survival (DFS) was not reached. Additionally, 61.5% of patients did not experience local recurrence or metastasis. Local recurrence was identified as an adverse prognostic factor for OS (NR vs 30 months, 95%CI 0.543–59.457, p = 0.037). Intracranial extension was identified as an adverse prognostic factor for DFS (NR vs. 7 months, 95%CI 0–14.321, p = 0.019).SNCs are rare and heterogeneous cancers that require a multidisciplinary management approach. Due to nonspecific symptoms, most patients are diagnosed at advanced stages. More prospective data are needed to optimize patient care.